RICHMOND, Calif., May 12, 2015 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (OTCQB:EKSO), a robotic exoskeleton company, announced today that it will be exhibiting at The 4 th International Spinal Cord Society (ISCoS) and American Spinal Injury Association (ASIA) Joint Scientific Meeting, taking place May 14-16, 2015 at the Fairmont Queen Elizabeth Hotel, Montreal, QC, Canada. Ekso Bionics will be featuring live demonstrations of their patented rehabilitation exoskeleton, Ekso GT™, and experts will be on hand at booth #10 to discuss the clinical applications.
"With the Ekso GT robotic exoskeleton, clinicians in leading rehabilitation facilities around the world can provide gait training for a large number of patients, with a range of lower extremity weakness. Ekso GT exoskeleton is unique in that it allows for the robotics to work with human effort, and not simply replace it," said Nathan Harding, chief executive officer and co-founder of Ekso Bionics. "This is just one of the reasons we have seen adoption and utilization significantly increase in the past year. In fact we just hit 21 million steps taken world wide by individuals with lower extremity weakness."
Ekso Bionics' exclusive Variable Assist software automatically adjusts robotic support based on patient capability for optimal training, which enables therapists to work with individuals with varying amounts of lower extremity weakness including stroke, SCI and other similar conditions. This feature is specifically designed to engage patients by challenging their abilities as they progress.
Ekso Bionics designs, develops, and commercializes exoskeletons, or wearable robots, which have a variety of applications in the medical, military and industrial markets. Over 125 Ekso GTs, the company's medical exoskeletons, are available to patients in nearly 100 leading rehabilitation centers all over the world and has enabled those living with a variety of lower extremity weakness to take over 21 million steps not otherwise possible.
About Ekso Bionics
Since 2005, Ekso Bionics has been pioneering the field of robotic exoskeletons, or wearable robots, to augment human strength, endurance and mobility. The company's first commercially available product called Ekso has helped thousands of people living with paralysis take millions of steps not otherwise possible. By designing and creating some of the most forward-thinking and innovative solutions for people looking to augment human capabilities, Ekso Bionics is helping people rethink current physical limitations and achieve the remarkable.
Ekso Bionics is headquartered in Richmond, CA and is listed on the OTC QB under the symbol EKSO. To learn more about Ekso Bionics please visit us at www.eksobionics.com
FORWARD-LOOKING STATEMENTS
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the design, development and commercialization of human exoskeletons, (ii) a projection of financial results, financial condition, capital expenditures, capital structure or other financial items, (iii) the Company's future financial performance and (iv) the assumptions underlying or relating to any statement described in points (i), (ii) or (iii) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain adequate financing to fund the Company's operations and necessary to develop or enhance our technology, the significant length of time and resources associated with the development of the Company's products, the Company's failure to achieve broad market acceptance of the Company's products, the failure of our sales and marketing organization or partners to market our products effectively, adverse results in future clinical studies of the Company's medical device products, the failure to obtain or maintain patent protection for the Company's technology, failure to obtain or maintain regulatory approval to market the Company's medical devices, lack of product diversification, existing or increased competition, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC. To learn more about Ekso Bionics please visit us at www.eksobionics.com . The Company does not undertake to update these forward-looking statements.
Facebook: www.facebook.com/eksobionics Twitter: @eksobionics YouTube: http://www.youtube.com/user/EksoBionics/
Media Contact: Heidi Darling, Director of Marketing Communications Phone: 510-984-1761 x317 E-mail: Investor Contact: Chad Rubin, Senior Vice President Phone: 646 378-2947 E-mail:
